AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00922207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly, from week 1-48
Study NCT00922207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly, from week 1-48
Study NCT02114645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
Study NCT02114645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected
Study NCT02114645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal progesterone
Description: crinone gel is applied till fetal heart beat is detected
Study NCT01802632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
Study NCT03705299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive CVP vs Standard CVP
Study NCT03781206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO™ 7
Description: PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
Study NCT02418806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy groups
Study NCT02418806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help groups
Study NCT04580199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: to excise the thyroid gland
Study NCT01490112 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
Study NCT02570295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Army Physical Fitness Training
Description: 2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
Study NCT00484575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: given by infusion via AnaConDa for sedation with target MAAS 2-3
Study NCT00484575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol given intravenously for sedation in control group
Study NCT02243813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
Study NCT04241224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy
Description: Endovascular treatment of peripheral arterial disease
Study NCT04209049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Study NCT02765672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Driving Assessment
Description: Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Propensity for Angry Driving Scale
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Propensity for Angry Driving Scale
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Integration Questionnaire
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Integration Questionnaire
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
Study NCT02447263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT01183871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of cerebral oxygenation
Description: The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
Study NCT03112213 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
Study NCT03112213 — intervention group
Intervention type: DRUG
Intervention: NSAIDs
Description: Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
Study NCT04209296 — intervention group
Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
Study NCT02273440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study NCT02273440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Study NCT02273440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline
Study NCT02273440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03566524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
Study NCT03566524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction with Life
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life
Description: This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
Study NCT04361643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.
Description: Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Study NCT04361643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Study NCT02840058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples
Study NCT02840058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti PD1/PDL1 treatment
Study NCT01262300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Virus Vaccine (Zostavax)
Description: Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
Study NCT00704509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 20 mg daily, encapsulated tablets, orally, 12 months
Study NCT00704509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablets, orally, 12 weeks
Study NCT00704509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 600 mg daily, encapsulated tablets, orally, 12 months
Study NCT02388516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT02388516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02390336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real mobilization-with-movement (MWM)
Description: For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
Study NCT02390336 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham mobilization-with-movement (MWM)
Description: In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
Study NCT02260102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temocillin
Description: Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
Study NCT01863849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB suspension for injection
Description: Single intramuscular injection with Fluval AB suspension for injection in both age groups
Study NCT02149836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine
Description: Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue
Study NCT01662700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Study NCT01662700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT00527215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
Study NCT00083070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT03632681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Insulin
Description: Intranasal insulin
Study NCT02114645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day
Study NCT03632681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal placebo manufactured to mimic smell of insulin
Study NCT02061722 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging with [18F]MNI-659
Description: The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.
Study NCT04569474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transparent dressing
Description: Use of sterile transparente dressing
Study NCT01429987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plecanatide
Description: Subjects receive experimental study drug for 12 weeks.
Study NCT01429987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive experimental study drug for 12 weeks.
Study NCT01745393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Quality Improvement + Behavioral Counseling
Study NCT01745393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Quality Improvement + Attention Control
Study NCT01301560 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
Study NCT01301560 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Observation
Description: No local treatment
Study NCT01794494 — intervention group
Intervention type: PROCEDURE
Intervention: Bypass surgery
Description: Patients are treated with femoro-popliteal bypass
Study NCT01794494 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular recanalization
Description: Patients are treated with PTA or subintimal angioplasty
Study NCT03308084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
Study NCT03308084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively
Study NCT03308084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administration of 10mg Dexamethasone IV intraoperatively
Study NCT02218814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block, Bupivacaine
Description: Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease.
Study NCT02218814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block, Bupivacaine
Description: Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.
Study NCT02539082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenseal
Description: Regenseal, collagen, injection in the defect area
Study NCT02539082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo, normal saline, injection in the defect area
Study NCT04500314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration device
Description: 20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
Study NCT04500314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physical therapy treatment
Description: The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
Study NCT04500314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy treatment
Description: The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
Study NCT02421367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Description: Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
Study NCT02198287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX inhalation solution
Description: single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
Study NCT02198287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01594632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jadelle
Description: LNG containing subdermal contraceptive implant
Study NCT01594632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sino-implant (II)
Description: LNG containing subdermal contraceptive implant
Study NCT03697928 — intervention group
Intervention type: OTHER
Intervention: Exercise metabolism
Description: Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
Study NCT02411201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTAREM
Description: Single intravenous injection of 0.1 mmol/kg body weight
Study NCT04402268 — intervention group
Intervention type: DEVICE
Intervention: Cardioverter-defibrillator
Description: We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
Study NCT03986346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
Study NCT03986346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized care
Description: the scar will receive standardized care such as scar massage.
Study NCT03986346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized care
Description: the scar will receive standardized care such as scar massage.
Study NCT04611685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.